^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Breast Cancer
    Drug:pegylated liposomal doxorubicin (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Caelyx pegylated liposomal is indicated:...as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk…